Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis
Status:
Terminated
Trial end date:
2020-02-19
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well busulfan, fludarabine, donor stem cell transplant, and
cyclophosphamide in treating participants with multiple myeloma or myelofibrosis. Drugs used
in chemotherapy, such as busulfan, fludarabine, and cyclophosphamide, work in different ways
to stop the growth of cancer cells, either by killing the cells, by stopping them from
dividing, or by stopping them from spreading. Giving chemotherapy before a donor stem cell
transplant helps stop the growth of cells in the bone marrow, including normal blood-forming
cells (stem cells) and cancer cells. When the healthy stem cells from a donor are infused
into the participant they may help the participant's bone marrow make stem cells, red blood
cells, white blood cells, and platelets. Giving busulfan and fludarabine before and
cyclophosphamide after donor stem cell may work better in treating participants with multiple
myeloma or myelofibrosis.